Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859339 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
A Phase 2 study, sponsored by Noah Hahn, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00859339: Clinical Trial Phase 2 study, sponsored by Noah Hahn, M.D..
NCT00859339 is a Phase 2 study that was terminated before completion, run by Noah Hahn, M.D.. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00859339, a Phase 2 study, was terminated before completion, sponsored by Noah Hahn, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
Primary Outcome
number of participants with a pCR
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- PROCEDURE Radical Cystectomy
- DRUG Sunitinib Malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-03 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Why NCT00859339 stopped before completion
NCT00859339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00859339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00859339 about?
NCT00859339 is a clinical study titled "Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC". This trial will investigate the activity of sunitinib combined with cisplatin and gemcitabine followed by radical cystectomy in patients with Transitional Cell Carcinoma (TCC) of the Bladder.
What is the current status of trial NCT00859339?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-03. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00859339?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Radical Cystectomy (PROCEDURE), Sunitinib Malate (DRUG).
Who is sponsoring clinical trial NCT00859339?
This trial is sponsored by Noah Hahn, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00859339's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia